Partnership on dCODE® Immunophenotyping Services Announced by Immudex and Parean
Immudex and Parean are pleased to announce a strategic partnership aimed at advancing immune cell phenotyping services for the pharmaceutical industry. By combining Immudex’s innovative dCODE®technology with Parean’s expertise in cytometry, cell sorting, single-cell multi-omics analysis, and computational biology, the collaboration provides cutting-edge solutions to study antigen-specific immune cells.
Immudex provides DNA barcoded dCODE® reagents for single-cell multi-omics analysis of antigen-specific B and T cells. dCODE® reagents link BCR/TCR sequences to the cognate antigen or peptide-MHC complex and can be combined with analysis of gene expression and surface protein expression for a comprehensive understanding of the adaptive immune response at single-cell resolution.
Parean, a France-based company, provides standard and tailored drug discovery tools and services for the biotech and pharmaceutical industry. Parean’s expertise includes flow cytometry, cell sorting, bulk and single-cell omics sequencing, and advanced data science operations. Parean’s ISO 9001-certified Quality Management System complies with high standards during early drug development phases in oncology and immune related diseases.
Through this strategic partnership, Immudex and Parean jointly offer a robust platform for the comprehensive characterization of antigen-specific immune cells, tailored to drug developers and cell therapy companies. Hence, biotech and pharma companies benefit from detailed TCR and BCR clonotype analysis, and deep immunophenotyping linking antigen specificity, gene expression and surface markers.
Henrik Pfundheller, CCO of Immudex, comments “Single-cell multi-omics profiling of antigen-specific immune cells yields vast amounts of valuable data, but both generating and interpreting these datasets can be challenging. Comprehensive analysis of immunology and genomics data is essential for driving innovation in cancer vaccines and immunotherapies. We are excited to collaborate with Parean, which specializes in both wet lab single-cell multi-omics experiments and advanced data analysis, providing researchers with a trusted partner for outsourcing their dCODE® experiments.”
Marwan Touati, CEO of Parean Biotechnologies, comments “Antigen specificity in immune cells is a powerful readout, particularly when combined with other omics. This approach provides deeper insights into immune response and supports the development of new TCR-based innovations. Our partnership with Immudex aligns with our strategy of selectively collaborating with technology providers, to strengthen and broaden our offering of cutting-edge immune bioassays. Moreover, dCODE® experiments are a key component of our recently launched TCR-Discovery Platform. Our extensive experience in TCR & BCR analysis, including T-Cell & B-Cell detection, sorting, culture and single-cell multi-omics, augmented by Immudex’s dCODE® platform, will help uncover new possibilities and targets for our biotech clients and partners.”
Further Information
dCODE® reagents are available for the analysis of antigen-specific CD8+ T cells, CD4+ T cells and B cells, as well as non-conventional T cells (MAIT cells and iNKT cells). Based on the Dextramer® technology, the high-avidity dCODE® reagents ensure even rare or low-affinity immune cells are analyzed. From high-throughput multiplex screening to monitoring of selected targeted antigen specificities, dCODE® is compatible with BD Rhapsody™ and 10x Chromium platforms.
Parean provides Wet Labs & Datascience Services focused on immune and tumor cells and is a 10x Genomics certified service provider.
Further information on:
- dCODE Dextramer® reagents and dCODE Klickmer® reagents from Immudex
- Services from Parean
About Immudex
Immudex ApS is a pioneering life science company and the trusted partner of scientists worldwide spearheading the global adoption of precision cellular immune monitoring. Immudex’s mission is to help researchers and clinicians unravel the complexity of the immune system, enabling the development of more effective immune-based therapeutics and diagnostics.
Immudex operates globally, with headquarters in Copenhagen, Denmark, and North American operations based in Philadelphia, Pennsylvania. Immudex’s Dextramer® technology is superior for the detection of antigen-specific immune cells, including rare and low-affinity cells. Immudex offers a broad product portfolio that allows scientists to investigate diverse types of immune cells, including T cells, non-conventional T cells and B cells, with reagents tailored to specific applications. Immudex’s products are compatible with multiple platforms from flow cytometry to next generation sequencing and single-cell multi-omics.
In addition to Dextramer® reagents for basic research, Immudex also provides Dextramer® (GMP) products and Dextramer® CMV Kits (IVD) manufactured in ISO 13485:2016-certified facilities, according to the requirements of FDA QSR 21 CFR 820. Immudex’s products enable scientists to get the full picture of the immune response, supporting ground-breaking advances within immuno-oncology, transplantation, autoimmune and infectious diseases. Find out more at www.immudex.com.
About Parean
Parean Biotechnologies is a leading European company supporting biotech, techbio, and pharmaceutical companies. Through collaboration or as a service provider, Parean offers cutting edge tools for immune and tumor cells phenotyping, across discovery, preclinical and clinical phases.
Based in France, Parean has its headquarters and wet labs in Saint-Malo, France, an office in Paris, while operating globally. Parean leverages cytometry, sorting, bulk and single-cell omics, advanced data science operations and AI-based predictive tools. By mastering wet labs bioassays, and biostatistics, Parean stands out as a unique partner, providing fully integrated services in immunology and oncology.
The team has more than 15 years of experience in cell characterization and computational biology and has published over 20 papers since company’s inception in 2021. Parean’s platform has broad applications, from TCR sequencing, cell therapy characterization, and immune response biomarkers, to AI-driven immunogenicity tools and TIL phenotyping. In addition, Parean recently launched its TCR-Discovery Platform, dedicated to biotech companies developing TCR-based therapies and biomarkers.
Parean is ISO 9001-certified company and an official 10x Genomics certified provider, ensuring consistent, robust operations for its clients and partners. Parean has also been granted the “CIR” agreement, a public tax incentive for clients with operations in France. Find out more at www.pareanbiotech.fr.
